16.2 Signature Page

Protocol Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Protocol Number: PXD101-**CLN-19**

Reviewed and Approved by:

Signature: _____ Date: 07 NOV 2013

Name: Lee F. Allen, MD, PhD
Title: Chief Medical Officer (CMO)
Department: Medical Development

Signature: _____ Date: 07 NOV 2013

Name: Anil Hiteshi, RAC
Title: Vice President
Department: Regulatory Affairs

Signature: _____ Date: 07 NOV 2013

Name: Lee F. Allen, MD, PhD
Title: CMO
Department: Interim Head Clinical Operations

Authorized Sponsor Representative Signature

Signature: _____ Date: 07 NOV 2013

Name: Lee F. Allen, MD, PhD
Title: CMO
Head of Medical Development

SIGNATURE OF THE PRINCIPAL INVESTIGATOR

Study Title: A Controlled Study of the Ability of a Traditional Swedish Smokeless Tobacco Product ("Snus") to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking

Protocol Number: SM 08-01

I have read this report and confirm that, to the best of my knowledge, it accurately describes the conduct and results of the study.

H. Frank Farmer Jr., MD, PhD, CPI
Covance Clinical Research Unit, Inc.

18 Dec 2012
Date

16.3 Title Page

The introduction should contain a brief statement (maximum: 1 page) placing the study in the context of the development of the test drug/investigational product, relating the critical features of the study (e.g., rationale and aims, target population,

Clinical Study Report: PXD101-CLN-19

Study Title:	**A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma**
Study Number:	PXD101-**CLN-19**
Study Phase:	2
Study Design:	Open-label, non-randomized, multicenter
Product Name:	Belinostat
Indication:	Relapsed or refractory peripheral T-cell lymphoma (PTCL)
First Patient Dosed:	11-May-2009
Case Report Form Data Cut-off:	31-Aug-2012
Principal Investigator:	Owen O'Connor, MD, PhD (see Appendix 16.1.5)
Sponsor:	Spectrum Pharmaceuticals, Inc. 157 Technology Drive Irvine, CA 92618 949-788-6700
Responsible Medical Officer:	Shanta Chawla, MD
Final Date:	05-Nov-2013

Any guidelines that were followed in the development of the protocol or any other agreements/meetings between the sponsor/company and regulatory authorities that are relevant to the particular study, should be identified or described. [Current use of bisphosphonates in oncology.]

Figure 4 - $CL_{ss/F}$ over the dose range tested



SAR260301 maximal concentrations were rapidly reached with t_{max} ranging from 0.5 to 1.5 hours post oral dosing, either on Day 1 and Day 28 (Table 1 and Table 2). Then concentrations decreased rapidly up to the last sampling time, 24 hours for QD or 12 hours for BID regimens (Figure 1 and Figure 2).

Overall, a moderate to high variability was observed for C_{max} with CV ranging from 29 % to 116%. A low to high variability was observed for AUC_T (CV ranging from 20 to 77%).

Based on mean values, the apparent total body clearance at steady state (CL_{ss}/F) remained almost constant over the dose range tested (100 mg BID to 800 mg BID) after repeated oral BID administration. Overall, CL_{ss}/F was 165 L/h (CV=42%).

After a single daily dose of 100 mg QD, the mean apparent elimination half-life was 5.2 hours.